VJOncology is committed to improving our service to you

ESMO 2019 | ClarIDHy: updates and initial findings for ivosidenib in CCA

VJOncology is committed to improving our service to you

Ghassan Abou-Alfa

Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, runs through the aims and initial findings of the ClarIDHy study (NCT02989857); a Phase III study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma (CCA) with an IDH1 mutation. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter